Holen Sie sich die Stockscreener-App
42.78
2.92%
1.215
Handel nachbörslich:
42.77
-0.015
-0.04%
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
EXEL: Former Executive Joins Recursion Pharmaceuticals as New CM - GuruFocus
Exelixis, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
EXEL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Quarterly Trades: Will Exelixis Inc outperform its industry peersMarket Volume Report & Capital Protection Trade Alerts - baoquankhu1.vn
Private Client Services LLC Takes $1.99 Million Position in Exelixis, Inc. $EXEL - MarketBeat
Here's why Exelixis (EXEL) is a strong value stock - MSN
Strategic Investment Advisors MI Buys 27,659 Shares of Exelixis, Inc. $EXEL - MarketBeat
How Exelixis Inc. (EXEL) Affects Rotational Strategy Timing - Stock Traders Daily
Pharma Stocks Analysis 2026: Pfizer & Novo Nordisk Rebound, Exelixis GrowthNews and Statistics - IndexBox
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
The Best Healthcare Stocks to Buy With $50 Right Now - The Motley Fool
Portfolio Update: What is the earnings history of Exelixis Inc2026 Highlights & AI Powered Trade Plan Recommendations - baoquankhu1.vn
L2 Asset Management LLC Invests $3.36 Million in Exelixis, Inc. $EXEL - MarketBeat
Exelixis (EXEL) Valuation After Earnings Beat FDA Progress And Cabometyx Label Expansion - Yahoo Finance
Exelixis, Inc. $EXEL Shares Acquired by Clark Capital Management Group Inc. - MarketBeat
Exelixis Highlights Zanzalintinib RCC Trials, Sequencing Debate, and December CRC PDUFA at Leerink - MarketBeat
Exelixis Highlights CABOMETYX Growth, Zanzalintinib PDUFA and Pipeline Strategy at Barclays Conference - MarketBeat
Exelixis Highlights $2.4B 2026 Outlook, Cabometyx Momentum and Zanzalintinib Catalysts at Conference - MarketBeat
Exelixis Inc Stock (ISIN: US30161Q1040) Gains Momentum on Earnings Beat and Zanzalintinib FDA Milest - AD HOC NEWS
Capital Impact Advisors LLC Boosts Stock Position in Exelixis, Inc. $EXEL - MarketBeat
How Exelixis’ Earnings Beat and FDA Zanzalintinib Milestone Will Impact Exelixis (EXEL) Investors - simplywall.st
Exelixis, Inc. $EXEL Stake Raised by South Street Advisors LLC - MarketBeat
Exelixis (NASDAQ:EXEL) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat
EXEL SEC FilingsExelixis Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing Exelixis (EXEL) Valuation After Analysts Lift 2026 Earnings Forecasts - simplywall.st
Schroder Investment Management Group Has $22.95 Million Stock Position in Exelixis, Inc. $EXEL - MarketBeat
Here's why Exelixis (EXEL) is a strong growth stock - MSN
Exelixis (EXEL) Down 2.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Here’s What Makes Exelixis (EXEL) a Top Growth Stock - Bitget
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
Exelixis at Barclays Healthcare: Strategic Growth and Pipeline Insights By Investing.com - Investing.com Canada
EXEL: Zanzalintinib and CABOMETYX anchor growth in GI/GU oncology, with robust pipeline momentum - TradingView
EXEL: Zanza and new indications drive growth, targeting $2.4B revenue and leadership in key oncology markets - TradingView
First Trust Advisors LP Has $59.35 Million Holdings in Exelixis, Inc. $EXEL - MarketBeat
Barclays PLC Boosts Stock Holdings in Exelixis, Inc. $EXEL - MarketBeat
Exelixis at Leerink Global Healthcare Conference: Strategic Insights in RCC and CRC - Investing.com Canada
Exelixis Q4 2025 slides: Strong earnings growth amid oncology franchise expansion - Investing.com Nigeria
Dimensional Fund Advisors LP Grows Holdings in Exelixis, Inc. $EXEL - MarketBeat
Victory Capital Management Inc. Acquires 187,034 Shares of Exelixis, Inc. $EXEL - MarketBeat
What is Zacks Research's Estimate for Exelixis Q3 Earnings? - MarketBeat
Crossmark Global Holdings Inc. Boosts Stock Position in Exelixis, Inc. $EXEL - MarketBeat
Exelixis, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
(EXEL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Teton Advisors LLC Makes New Investment in Exelixis, Inc. $EXEL - MarketBeat
Exelixis (NASDAQ:EXEL) Cut to Hold at Zacks Research - MarketBeat
Gainers Report: Will Exelixis Inc benefit from rising consumer demandWeekly Trend Summary & Smart Investment Allocation Tips - baoquankhu1.vn
Exelixis, Inc. (NASDAQ:EXEL) Given Average Recommendation of "Hold" by Analysts - MarketBeat
American Century Companies Inc. Raises Position in Exelixis, Inc. $EXEL - MarketBeat
Elo Mutual Pension Insurance Co Buys 30,279 Shares of Exelixis, Inc. $EXEL - MarketBeat
A Look At Exelixis (EXEL) Valuation As Analyst Optimism Builds Around Its Oncology Pipeline - simplywall.st
EXEL: Zanzalintinib advances toward launch as pivotal trials and franchise expansion drive future growth - TradingView
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):